Canada’s next wave of healthcare innovation is increasingly taking shape at the convergence of artificial intelligence, diagnostics, digital platforms, medical devices, and more accessible patient care models. Five developing HealthTech businesses from Toronto Metropolitan University’s Brampton Venture Zone are showcasing their potential at Brampton Venture Expo 2026, where they have advanced to the Mitacs Health Innovation Showcase finals. The finalists include Alex Arrazaghi of Athel AI, Mazhar Shahen of NewGen Health, Sahil Manjania of DIA Labs Canada, Angélique Bernabé of LOCVM, and Mussab Tauseef of LBx Bio. They are working together to develop technology that will address issues such as clinical administration and physician staffing, as well as asthma monitoring, at-home screening and cancer detection.
The five finalists were chosen from ten early-stage companies that took part in the BVZ Health Innovation Showcase on August 13 at Toronto Metropolitan University’s School of Medicine in Brampton. They are competing for up to $70,000 in non-dilutive funding to support further development and commercialization. For Canadian founders, their development demonstrates something as important: innovative healthcare concepts require more than technology. They require validation, financing, industry links, commercialization support, and opportunities to meet with the people who can help them reach the market.
Athel AI: Bringing Intelligence Into the Clinical Workflow
Founder Alex Arrazaghi is developing Athel AI, an autonomous clinical operating system intended to address one of healthcare’s ongoing challenges: the administrative workload associated with patient care. The platform is being built to offer specialty care teams decision-ready patient intelligence before an appointment begins. Athel AI promises to reduce administrative load by organizing key clinical information early in the process, allowing physicians to focus more on care and decision-making.
The initiative illustrates AI’s rising significance in healthcare, not just as a tool for data generation, but as infrastructure that can improve clinical workflow and delivery. This distinction matters for healthcare innovation. Successful AI adoption will increasingly rely on technology’s ability to integrate meaningfully into existing workflows and solve recognizable operational issues.
NewGen Health: Moving Health Monitoring Into the Home
Mazhar Shahen’s NewGen Health is developing a device-enabled SaaS platform to expand prenatal screening and chronic illness monitoring beyond typical clinical settings. Its technology converts home urine testing results into trackable health data that professionals may use. The strategy reflects a broader healthcare trend: a shift toward decentralized, networked care. As digital health technology advances, patients will be able to collect important health information between sessions. Instead of merely collecting more consumer data, the business potential lies in making that information accurate, actionable, and linked to professional care. NewGen Health has positioned its technology for this shift.
DIA Labs Canada: Advancing More Personalized Asthma Monitoring
Understanding inflammatory activity can help people with moderate to severe asthma control their condition. Sahil Manjania and DIA Labs Canada are developing a unique Class II medical device to monitor inflammatory biomarkers at the point of care. The system is intended to deliver real-time information that can be used to make more tailored treatment decisions and improve condition management. DIA Labs is another big Canadian HealthTech opportunity: bringing diagnostic information closer to patients and practitioners.
Point-of-care technologies can help bridge the gap between testing, interpretation, and treatment decisions. For entrepreneurs in this field, however, the journey to market includes product validation, healthcare uptake, legislation, clinical evidence, production, and commercialization. Programs that connect creators with industry and healthcare partners can play an essential role in advancing promising medical ideas beyond the prototype stage.
LOCVM: Tackling a Healthcare Workforce Challenge
Not all healthcare innovations start with a new medical gadget. Angélique Bernabé’s LOCVM approaches healthcare delivery differently: it helps physicians and clinics connect more efficiently when temporary physician coverage is needed. The healthcare locum marketplace connects physicians with locum opportunities and helps clinics identify vetted individuals available to provide temporary coverage.
Its model demonstrates how technology can help address healthcare concerns by improving labour market infrastructure and coordination. Workforce availability remains directly tied to patient access, clinic capacity, and service continuity. Digital marketplaces that can reduce friction between available experts and healthcare institutions may become an increasingly important component of health system innovation.
LBx Bio: Bringing Cancer Detection Closer to the Point of Care
Mussab Tauseef’s LBx Bio is addressing one of the most important aspects of diagnostics: cancer detection. The company is developing a quick, low-cost, point-of-care liquid biopsy technology designed to detect cancer during the same clinical visit. Its goal is to bring molecular diagnostics closer to the point where patients receive treatment. Liquid biopsy technologies are part of a fast-expanding discipline that aims to harness biological information present in bodily fluids to detect disease. For LBx Bio, commercialization prospects depend not only on diagnostic performance, but also on accessibility, speed, and how well the technology fits into real-world clinical settings. It is a bold example of deep technology emerging from Canada’s early-stage HealthTech industry.
From Startup Incubation to Commercialization
The five finalists are part of BVZ Launch, Brampton Venture Zone’s four-month non-equity incubator for MVP-ready HealthTech and wellness startups. Participants receive mentorship and commercialization assistance while focusing on product-market fit, market entry, industry relationships, validation possibilities, and prospective pilots. That framework addresses a crucial challenge for many technology founders: creating a viable product is only the first step in building a sustainable business. Entrepreneurs, particularly in healthcare, must understand clients, regulatory procedures, clinical requirements, procurement environments, fundraising, collaborations, and commercialization.
Brampton Venture Zone has been developing infrastructure to support that trip. Since its inception in 2020, BVZ has helped 140 businesses, enabled 108 industry pilots, and claimed a 77% alumni retention rate. Its broader ecosystem collaborates with Toronto Metropolitan University’s School of Medicine and Invest Brampton, linking entrepreneurship to healthcare, research, technology, and economic growth.
Brampton’s Growing HealthTech Opportunity
The five finalists also represent a bigger vision for Brampton. With Toronto Metropolitan University’s School of Medicine, a diverse and growing population, healthcare institutions, municipal economic development initiatives, and an expanding startup ecosystem, the city is creating conditions to support more HealthTech companies, from early validation to commercialization. Zied Etleb, Senior Director of Toronto Metropolitan University’s Brampton Venture Zone, described the opportunity as one that could deliver both healthcare impact and support Brampton-based firms by giving entrepreneurs the relationships and validation they need to grow. The Mitacs Health Innovation Showcase brings the ecosystem together in a very practical way.
The five entrepreneurs will pitch to investors, healthcare experts, corporate innovators, ecosystem leaders, and potential partners, with three startups receiving up to $70,000 in non-dilutive capital. The exhibition is part of BVX 2026, which will bring together over 1,500 founders, investors, SMEs, researchers, healthcare professionals, legislators, and innovation partners around the topic “Where Industry Meets Innovation.”
Five Companies, One Bigger Innovation Story
Athel AI, NewGen Health, DIA Labs Canada, LOCVM, and LBx Bio are all tackling very diverse problems, yet their journeys share a common thread. Each is seeking to advance a developing healthcare solution from concept or early product to measurable market and patient effect. This transformation is essential to Canada’s innovation economy. The strength of a HealthTech ecosystem is not solely determined by the number of potential technologies it develops. It depends on how well those innovations can be validated, funded, adopted, commercialized, and scaled.
As these five founders take to the BVX stage, they represent more than just a startup competition. They provide insight into the firms, technologies, and entrepreneurial talent shaping the next chapter of Canadian healthcare innovation. As an Official Media and Storytelling Partner of BVX 2026, CanadianSME Small Business Magazine is pleased to highlight the entrepreneurs and new technologies driving Brampton’s expanding innovation ecosystem.
Your role in staying up to date is integral to our shared mission of fostering a community of innovators. CanadianSME Magazine is a valuable treasure trove of entrepreneurial knowledge. Click here to subscribe to our monthly editions for updates on Canadian businesses. Follow our handle, @canadian_sme, on X to stay updated on all business trends and developments. Your support is crucial to our mission.
Disclaimer: This article is based on publicly available information and is intended only for informational purposes. CanadianSME Small Business Magazine does not endorse or guarantee any products or services mentioned. Readers are advised to conduct their research and due diligence before making business decisions.
